London Regional Cancer Program - London HSC ( Site 0107)

London, Ontario N6A 4L6

0 studies enrolling now · 1 studies all time

What they study most

Renal Cell Carcinoma

Studies at this site

• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) — Completed